Danirixin
Nov 28, 2017
Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial
Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
